Listed

Collegium Pharmaceutical, Inc: Form 10-Q for the period ended Jun 30, 2018

Filed with the SEC on Aug 8, 2018 and accepted by EDGAR at Aug 8, 2018, 16:03 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2018-04-01 to 2018-06-30$73.1mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2018-01-01 to 2018-06-30$136.8mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2018-04-01 to 2018-06-30$46.8mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue6 months2018-01-01 to 2018-06-30$89.9mus-gaap:CostOfGoodsAndServicesSold
Research and development3 months2018-04-01 to 2018-06-30$2.2mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2018-01-01 to 2018-06-30$4.5mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2018-04-01 to 2018-06-30$31.3mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2018-01-01 to 2018-06-30$62.9mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2018-04-01 to 2018-06-30−$7.3mus-gaap:OperatingIncomeLoss
Operating income6 months2018-01-01 to 2018-06-30−$20.5mus-gaap:OperatingIncomeLoss
Interest expense3 months2018-04-01 to 2018-06-30$6.2mus-gaap:InterestExpense
Interest expense6 months2018-01-01 to 2018-06-30$11.9mus-gaap:InterestExpense
Net income3 months2018-04-01 to 2018-06-30−$13.1mus-gaap:NetIncomeLoss
Net income6 months2018-01-01 to 2018-06-30−$31.7mus-gaap:NetIncomeLoss
Diluted EPS6 months2018-01-01 to 2018-06-30−$0.96us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow6 months2018-01-01 to 2018-06-30$85.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2018-01-01 to 2018-06-30$987.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2018-06-30$133.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-06-30$216.3mus-gaap:AssetsCurrent
Total assetsAt period end2018-06-30$673.3mus-gaap:Assets
Current liabilitiesAt period end2018-06-30$264.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-06-30$590.6mus-gaap:Liabilities
Long-term debtAt period end2018-06-30$11.5mus-gaap:LongTermDebt
Shareholders' equityAt period end2018-06-30$82.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001558370-18-006748. Last ingested by Listed: Nov 10, 2026, 23:07 ET. Listed shows no prices and gives no investment advice.